What We're Reading: Page 119
Industry reads hand-picked by our editors
Nov 10, 2022
-
The New York Times
The Disease Took Zara, Then Sara. Could Ayla Be Saved?
-
Financial Times
Psychedelics and business could make for a bad trip
-
Reuters
U.S. FDA panel votes against Veru’s COVID-19 pill
Nov 09, 2022
-
Financial Times
Patent wars: Moderna’s battle for the spoils of Covid vaccines
-
The Boston Globe
Pfizer dominates the COVID drug market. This Watertown biotech wants to change that.
-
FierceBiotech
FDA panel delivers mixed verdict on AstraZeneca’s asthma drug
-
Bloomberg
Pfizer to Enforce 2-3 Days of Weekly Office Work in January
Nov 08, 2022
-
STAT
J&J’s Mammen out of the running for Biogen CEO post
-
Reuters
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
-
FierceBiotech
ADC therapy sidelined after FDA nixes accelerated review chance
-
The Wall Street Journal
Political Gridlock Would Bring Big Pharma a Sigh of Relief
Nov 07, 2022
Nov 04, 2022
-
The Wall Street Journal
Teva Pharmaceutical to Replace CEO Kare Schultz
-
Stat News
FDA approval decision on Apellis Pharma eye disease drug delayed
-
Bloomberg
Sanofi, Astra Drug That Protects Infants from RSV Approved in Europe
-
Evaluate Vantage
If at first... pharma’s most drawn-out development timelines revealed
Nov 03, 2022
Nov 02, 2022
-
The Wall Street Journal
JPMorgan Launches Life-Sciences Venture Group
-
Evaluate Vantage
GSK struggles to shake Zantac and pipeline concerns
-
PR Week
FDA Commissioner Robert Califf plans to keep tweeting amid Elon Musk upheaval
Previous
